Transarterial chemoembolization for hepatocellular carcinoma: Development and external validation of the Munich-TACE score

Mark Op Den Winkel, Dorothea Nagel, Philip Op Den Winkel, Jörg Trojan, Philipp M. Paprottka, Christian J. Steib, Laura Schmidt, Markus Göller, Petra Stieber, Peter Göhring, Andreas Herbst, Markus Rentsch, Enrico N. De Toni, Burkhard Göke, Alexander L. Gerbes, Frank T. Kolligs

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Background Allocation of patients with hepatocellular carcinoma (HCC) to the adequate therapy is determined by both tumor burden and liver function. The Barcelona Clinic Liver Cancer (BCLC) staging system and therapeutic algorithm recommends transarterial chemoembolization (TACE) based on the best evidence available to patients with intermediate-stage HCC (BCLC-B). However, many centers also treat subgroups of patients outside these recommendations and with more advanced disease by TACE. The purpose of this study was to identify prognostic factors in a TACE cohort, including BCLC-B patients, as well as patients treated outside of BCLC-B, to test the prognostic capabilities of published staging systems and to optimize prognostication for TACE patients. Patients and methods A cohort of 186 first-line TACE patients was analyzed. Independent prognostic factors were identified and used to construct the Munich-TACE score (M-TACE). M-TACE was tested against established staging systems (including BCLC and two recently published TACE-specific scores) and a ranking using concordance index and Akaike Information Criterion was performed. Finally, an external validation in an independent TACE cohort (n=71) was conducted. Results Bilirubin, Quick/international normalized ratio, C-reactive protein, creatinine, α-feto protein, and tumor extension were identified as independent prognostic factors and used to construct M-TACE. M-TACE identifies three distinct subgroups (P<0.0001) with median survival times of 35.2, 16.9, and 8.6 months, respectively. Compared with established staging systems, M-TACE showed the best prognostic capabilities in both cohorts of patients (cohort 1: C-index, 0.71; Akaike Information Criterion: 1276; cohort 2: C-index, 0.754). Conclusion We identified independent risk factors for patients treated with TACE. The newly constructed M-TACE score is superior to established staging systems and might prove helpful to identify patients who are most suitable for TACE.

Original languageEnglish
Pages (from-to)44-53
Number of pages10
JournalEuropean Journal of Gastroenterology and Hepatology
Issue number1
StatePublished - Jan 2018
Externally publishedYes


  • Barcelona Clinic Liver Cancer
  • Cancer of the Liver Italian Program
  • Hepatocellular carcinoma staging systems
  • Hepatoma Arterial embolization Prognostic
  • Selection for Transarterial Chemoembolization Treatment


Dive into the research topics of 'Transarterial chemoembolization for hepatocellular carcinoma: Development and external validation of the Munich-TACE score'. Together they form a unique fingerprint.

Cite this